Diversification is crucial, but the company lacks it. Heavy R&D investments have yet to yield profitable results, and the decline in COVID vaccine sales has contributed to shrinking revenue and a less-than-ideal financial position. Given these factors, I believe the Q4 earnings report may fall short of expectations, likely leading to a significant dip. I plan to sell now before that happens.
There are no replies in this thread yet. Be the first to post a reply below: